FY2025 Earnings Estimate for GENFIT Issued By HC Wainwright

GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT) – Research analysts at HC Wainwright reduced their FY2025 EPS estimates for GENFIT in a report issued on Wednesday, September 24th. HC Wainwright analyst B. Folkes now anticipates that the company will earn ($0.17) per share for the year, down from their prior estimate of $0.01. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for GENFIT’s current full-year earnings is $0.95 per share. HC Wainwright also issued estimates for GENFIT’s FY2026 earnings at ($0.63) EPS, FY2027 earnings at $0.15 EPS, FY2028 earnings at ($0.51) EPS and FY2029 earnings at ($0.28) EPS.

GENFIT Stock Performance

GNFT stock opened at $3.52 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.74 and a quick ratio of 1.23. GENFIT has a 12 month low of $2.55 and a 12 month high of $6.42. The firm has a 50-day moving average price of $3.99 and a 200-day moving average price of $3.90.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in GENFIT stock. OLD Mission Capital LLC acquired a new stake in GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 22,238 shares of the company’s stock, valued at approximately $76,000. 2.24% of the stock is currently owned by institutional investors and hedge funds.

GENFIT Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.